相似文献
1
Human primary immunodeficiency caused by expression of a kinase-dead p110δ mutant.
J Allergy Clin Immunol. 2019 Feb;143(2):797-799.e2. doi: 10.1016/j.jaci.2018.10.005. Epub 2018 Oct 16.
2
E1021K Homozygous Mutation in PIK3CD Leads to Activated PI3K-Delta Syndrome 1.
J Clin Immunol. 2020 Feb;40(2):378-387. doi: 10.1007/s10875-020-00749-y. Epub 2020 Jan 17.
3
A novel monoallelic gain of function mutation in p110δ causing atypical activated phosphoinositide 3-kinase δ syndrome (APDS-1).
Clin Immunol. 2019 Mar;200:31-34. doi: 10.1016/j.clim.2019.01.003. Epub 2019 Jan 9.
4
Paediatric MAS/HLH caused by a novel monoallelic activating mutation in p110δ.
Clin Immunol. 2020 Oct;219:108543. doi: 10.1016/j.clim.2020.108543. Epub 2020 Jul 16.
5
PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
Endocr Metab Immune Disord Drug Targets. 2019;19(7):941-958. doi: 10.2174/1871530319666190225114739.
6
Hemophagocytic Lymphohistiocytosis in Activated PI3K Delta Syndrome: an Illustrative Case Report.
J Clin Immunol. 2021 Oct;41(7):1656-1659. doi: 10.1007/s10875-021-01080-w. Epub 2021 Jun 11.
7
Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency.
J Allergy Clin Immunol. 2016 Dec;138(6):1672-1680.e10. doi: 10.1016/j.jaci.2016.03.055. Epub 2016 Jul 14.
8
Dual loss of p110δ PI3-kinase and SKAP (KNSTRN) expression leads to combined immunodeficiency and multisystem syndromic features.
J Allergy Clin Immunol. 2018 Aug;142(2):618-629. doi: 10.1016/j.jaci.2017.10.033. Epub 2017 Nov 26.
9
Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome.
Cytometry B Clin Cytom. 2021 Jul;100(4):460-466. doi: 10.1002/cyto.b.21956. Epub 2020 Sep 22.
10
Case Report: Activating Mutation in Patients Presenting With Granulomatosis With Polyangiitis.
Front Immunol. 2021 Apr 28;12:670312. doi: 10.3389/fimmu.2021.670312. eCollection 2021.
引用本文的文献
1
mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node.
Orphanet J Rare Dis. 2025 May 27;20(1):256. doi: 10.1186/s13023-025-03740-1.
2
Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives.
Immunother Adv. 2024 Nov 7;4(1):ltae009. doi: 10.1093/immadv/ltae009. eCollection 2024.
3
Genetic Etiologies and Outcomes in Malignancy and Mortality in Activated Phosphoinositide 3-Kinase Delta Syndrome: A Systematic Review.
Adv Ther. 2025 Feb;42(2):752-771. doi: 10.1007/s12325-024-03066-7. Epub 2024 Dec 5.
4
Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective.
J Clin Immunol. 2023 Dec 27;44(1):34. doi: 10.1007/s10875-023-01626-0.
5
PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond.
J Allergy Clin Immunol Pract. 2024 Jan;12(1):69-78. doi: 10.1016/j.jaip.2023.09.016. Epub 2023 Sep 28.
6
PI3K Isoforms in B Cells.
Curr Top Microbiol Immunol. 2022;436:235-254. doi: 10.1007/978-3-031-06566-8_10.
7
Inherited immunodeficiencies associated with proximal and distal defects in T cell receptor signaling and co-signaling.
Biomed J. 2022 Apr;45(2):321-333. doi: 10.1016/j.bj.2022.01.013. Epub 2022 Jan 25.
8
PI3K in T Cell Adhesion and Trafficking.
Front Immunol. 2021 Aug 6;12:708908. doi: 10.3389/fimmu.2021.708908. eCollection 2021.
9
PI3K inhibitors are finally coming of age.
Nat Rev Drug Discov. 2021 Oct;20(10):741-769. doi: 10.1038/s41573-021-00209-1. Epub 2021 Jun 14.
10
Flow Cytometry-Based Protocols for the Analysis of Human Plasma Cell Differentiation.
Front Immunol. 2020 Sep 29;11:571321. doi: 10.3389/fimmu.2020.571321. eCollection 2020.
本文引用的文献
1
Primary immunodeficiency disorder caused by phosphoinositide 3-kinase δ deficiency.
J Allergy Clin Immunol. 2018 Nov;142(5):1650-1653.e2. doi: 10.1016/j.jaci.2018.06.039. Epub 2018 Jul 21.
2
Dual loss of p110δ PI3-kinase and SKAP (KNSTRN) expression leads to combined immunodeficiency and multisystem syndromic features.
J Allergy Clin Immunol. 2018 Aug;142(2):618-629. doi: 10.1016/j.jaci.2017.10.033. Epub 2017 Nov 26.
3
The PI3K Pathway in Human Disease.
Cell. 2017 Aug 10;170(4):605-635. doi: 10.1016/j.cell.2017.07.029.
4
PI3Kδ and primary immunodeficiencies.
Nat Rev Immunol. 2016 Nov;16(11):702-714. doi: 10.1038/nri.2016.93. Epub 2016 Sep 12.
5
Profiling lymphocyte interactions at the single-cell level by microfluidic cell pairing.
Nat Commun. 2015 Jan 13;6:5940. doi: 10.1038/ncomms6940.
6
Innate PI3K p110δ regulates Th1/Th17 development and microbiota-dependent colitis.
J Immunol. 2014 Apr 15;192(8):3958-68. doi: 10.4049/jimmunol.1301533. Epub 2014 Mar 14.
7
The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.
Sci Signal. 2010 Aug 10;3(134):ra60. doi: 10.1126/scisignal.2001104.
8
A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation.
J Exp Med. 2002 Sep 16;196(6):753-63. doi: 10.1084/jem.20020805.
9
Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.
Science. 2002 Aug 9;297(5583):1031-4. doi: 10.1126/science.1073560. Epub 2002 Jul 18.
Zotero 插件